Skip to Content

'
James W. Welsh, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2003 Dartmouth School of Medicine, Hanover, NH, MD, Medicine
1997 University of California, Davis, CA, BS, Genetics

Postgraduate Training

7/2004-6/2008 Clinical Residency, Radiation Oncology, The University of Arizona Health Sciences Center, Tucson, AZ
7/2003-6/2004 Clinical Internship, Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH

Board Certifications

7/2009 American Board of Radiology, Radiation Oncology

Experience/Service

Other Appointments/Responsibilities

Research Associate, Dartmouth Hitchcock Medical Center, Lebanon, NH, 7/2003-12/2003
Research Associate, Division of Molecular Oncology, Genentech, Inc, San Francisco, CA, 5/1997-8/1999
Research Assistant, University of California Davis Medical School, Davis, CA, 9/1996-4/1997

Institutional Committee Activities

Board Member, Center for Professional Development and Entrepreneurship Board of Advisors, 2013-present
Member, Medical Practice Committee, 2012-2013
Member, American Society of Radiation Oncology Research Evaluation, 2009-present

Honors and Awards

2012 Educational Grant, Hiroshima International Council for Health Care of the Radiation-Exposed (HICARE), Hiroshima International Council for Health Care
2009 Honorarium and Plaque, American College of Veterinary Radiation
2008 Honorarium, Chicago Multidisciplinary Symposium in Thoracic Oncology, American Society of Radiation Oncology
2007 Methods in Clinical Cancer Research Award, American Society of Clinical Oncology
2007 Roentgen Resident/Fellow Research Award, Radiological Society of North America
2006 Best of American Brachytherapy Society, American Brachytherapy Society
2006 Best of ASTRO Translational Research Symposium, American Society of Radiation Oncology
2006 First Place Abstract, Los Angeles Radiological Society Annual Meeting
2006 Travel Grant Award, American Brachytherapy Society
2005 Translational Research Symposium Travel Grant, American Society of Radiation Oncology

Professional Memberships

American Association for Cancer Research
Member, 2009-present
American Society of Radiation Oncology
Member, 2008-present
Radiation Therapy Oncology Group
Member, 2009-present
Radiological Society of North America
Member, 2009-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Hayashi Y, Xiao L, Suzuki A, Blum M, Sabloff B, Maru D, Welsh J, Lee JH, Bhutani M, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with esophageal cancer. Eur J Cancer. In Press.
2. Cheedella KS, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welsh J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. In Press.
3. Yang J, Amini A, Williamson R, Zhang L, Zhang Y, Komaki R, Liao Z, Cox J, Welsh J, Court L, Dong L. Automatic contouring of brachial plexus using a multi-atlas approach for lung cancer radiotherapy. Pract Radiat Oncol 3(4), 10/2013. PMCID: PMC3833708.
4. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh J, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52(5):1002-1009, 6/2013. e-Pub 9/2012. PMID: 22950385.
5. Wang HM, Liao ZX, Komaki R, Welsh J, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24(5):1312-1319, 5/2013. e-Pub 1/2013. PMCID: PMC3629895.
6. Bhardwaj V, Cascone T, Cortez MA, Amini A, Evans J, Komaki RU, Heymach JV, Welsh J. Modulation of c-met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer 119(10):1768-1775, 5/2013. e-Pub 2/2013. PMCID: PMC3648606.
7. Evans JD, Gomez DR, Amini A, Rebueno N, Allen PK, Martel MK, Rineer JM, Ang KK, McAvoy S, Cox JD, Komaki R, Welsh J. Aortic dose constraints when reirradiating thoracic tumors. Radiother Oncol 106(3):327-332, 3/2013. e-Pub 2/2013. PMID: 23453540.
8. Welsh J, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer. J Clin Oncol 31(7):895-902, 3/2013. e-Pub 1/2013. PMID: 23341526.
9. Gomez DR, Hong DS, Allen PK, Welsh J, Mehran RJ, Tsao AS, Liao Z, Bilton SD, Komaki R, Rice DC. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol 8(2):238-245, 2/2013. e-Pub 12/2012. PMID: 23247629.
10. Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer 48(18):3396-3404, 12/2012. e-Pub 7/2012. PMID: 22853875.
11. Shirvani SM, Jiang J, Chang JY, Welsh J, Gomez DR, Swisher S, Buchholz TA, Smith BD. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 84(5):1060-1070, 12/2012. e-Pub 9/2012. PMID: 22975611.
12. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 23(10):2638-2642, 10/2012. e-Pub 7/2012. PMCID: PMC3457750.
13. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Suzuki A, Lee JH, Bhutani MS, Welsh J, Lin SH, Maru DM, Swisher SG, Ajani JA. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus 25(7):614-622, 9/2012. e-Pub 12/2011. PMID: 22150920.
14. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2(9):798-811, 9/2012. e-Pub 9/2012. PMID: 22961666.
15. Bhardwaj V, Zhan Y, Cortez MA, Ang KK, Molkentine D, Munshi A, Raju U, Komaki R, Heymach JV, Welsh J. c-MET inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol 7(8):1211-1217, 8/2012. e-Pub 5/2012. PMCID: PMC3399033.
16. Amini A, Xiao L, Allen PK, Suzuki A, Hayashi Y, Liao Z, Hofstetter W, Crane C, Komaki R, Bhutani MS, Lee JH, Ajani JA, Welsh J. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys 83(2):e231-e239, 6/2012. e-Pub 3/2012. PMID: 22436793.
17. Welsh J, Settle S, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 118(10):2632-2640, 5/2012. e-Pub 10/2011. PMID: 22565611.
18. Yin M, Liao Z, Yuan X, Guan X, O'Reilly MS, Welsh J, Wang LE, Wei Q. Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci 103(5):945-950, 5/2012. e-Pub 3/2012. PMCID: PMC3337362.
19. Amini A, Yang J, Williamson R, McBurney ML, Erasmus J, Allen PK, Karhade M, Komaki R, Liao Z, Gomez D, Cox JD, Dong L, Welsh J. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int J Radiat Oncol Biol Phys 82(3):e391, 3/2012. PMID: 22284035.
20. Harvin JA, Lahat G, Correa AM, Lee J, Maru D, Ajani J, Marom EM, Welsh J, Bhutani MS, Walsh G, Roth J, Mehran R, Vaporciyan A, Rice D, Swisher S, Hofstetter W. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg 143(2):412-420, 2/2012. e-Pub 12/2011. PMID: 22172216.
21. Cortez MA, Welsh J, Calin GA. Circulating microRNAs as non-invasive biomarkers in breast cancer. Recent Results Cancer Res 195:151-61, 1/2012. PMID: 22527502.
22. Kim JY, Correa AM, Vaporciyan AA, Roth JA, Mehran RJ, Walsh GL, Rice DC, Ajani JA, Maru DM, Bhutani MS, Welsh J, Marom EM, Swisher SG, Hofstetter WL. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg 93(1):207-212; discussion 212-213, 1/2012. e-Pub 10/2011. PMID: 21962263.
23. Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 82(1):468-474, 1/2012. e-Pub 12/2010. PMID: 21123005.
24. Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, Mehran RJ, Roth JA, Swisher SG. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol 7(152):1-10, 2012. e-Pub 9/2012. PMCID: PMC3444889.
25. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh J, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology 82(2):108-113, 2012. e-Pub 2/2012. PMID: 22328056.
26. Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, Zhu XR, Likhacheva A, Liao Z, Hofstetter WL, Ajani JA, Cox JD. Intensity-modulated proton therapy further reduces normal-tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 81(5):1336-1342, 12/2011. e-Pub 4/2011. PMID: 21470796.
27. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 117(21):4823-4833, 11/2011. e-Pub 3/2011. PMCID: PMC3144261.
28. Welsh J, Thomas J, Shah D, Allen PK, Wei X, Mitchell K, Gao S, Balter P, Komaki R, Chang JY. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 81(1):91-96, 9/2011. PMID: 20542388.
29. Ajani JA, Blum MA, Welsh J, Hofstetter WL, Swisher SG. Celebrate or calibrate? We say calibrate. J Clin Oncol 29(19):2732-2733, 7/2011. e-Pub 5/2011. PMID: 21606421.
30. Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep 13(3):157-167, 6/2011. PMID: 21365188.
31. Turner LM, Howard JA, Dehghanpour P, Barrett RD, Rebueno N, Palmer M, Vedam S, Klopp A, Komaki R, Welsh J. Exploring the feasibility of dose escalation positron emission tomography-positive disease with intensity-modulated radiation therapy and the effects on normal tissue structures for thoracic malignancies. Med Dosim 36(4):383-388, 2011. e-Pub 12/2010. PMID: 21144734.
32. Nguyen NP, Bishop M, Borok TJ, Welsh J, Hamilton R, Cohen D, Nguyen LM, Vincent VH. Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: potential role for stereotactic body radiotherapy. Anticancer Res 30(3):953-961, 3/2010. PMID: 20393019.
33. Welsh J, Ellsworth RK, Kumar R, Fjerstad K, Martinez J, Nagel RB, Eschbacher J, Stea B. Rad51 protein expression and survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 74(4):1251-1255, 7/2009. PMID: 19545791.
34. Olsen CC, Welsh J, Kavanagh BD, Franklin W, McCarter M, Cardenes HR, Gaspar LE, Schefter TE. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 73(5):1414-1424, 4/2009. e-Pub 11/2008. PMID: 18990508.
35. Nguyen NP, Borok TL, Welsh J, Vinh-Hung V. Safety and effectiveness of vascular endoprosthesis for malignant superior vena cava syndrome. Thorax 64(2):174-178, 2/2009. PMID: 19176843.
36. Welsh J, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B. The c-MET receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 4(69):69, 2009. e-Pub 12/2009. PMCID: PMC2806296.
37. Nguyen NP, Garland L, Welsh J, Hamilton R, Cohen D, Vinh-Hung V. Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma. Cancer Treat Rev 34(8):719-727, 12/2008. e-Pub 7/2008. PMID: 18657910.
38. Ellsworth R, Welsh J, Mahadevan D, Bearrs D, Hsieh D, Fjerstad HK, Marsella M, Sanan A, Badrudoja M, Stea B. The radiosensitizing effects of a novel tyrosine kinase inhibitor, Mp470, in glioblastoma multiforme stem cells. Int J Radiat Oncol Biol Phys 72(1):S714-S715, 9/2008.
39. Nguyen NP, Vos P, Lee H, Borok TL, Karlsson U, Martinez T, Welsh J, Cohen D, Hamilton R, Nguyen N, Nguyen LM, Vinh-Hung V. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer. Oncology 75(3-4):186-191, 2008. e-Pub 10/2008. PMID: 18841033.
40. Welsh J, Abhay S, Gabayan A, Green SB, Lustig R, Burri S, Kwong E, Baldassarre S. GliaSite radiotherapy boost as part of initial treatment of malignant gliomas: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 68(1):159-165, 2007.
41. Xu L, Corcoran RB, Welsh J, Pennica D, Levine AJ. WISP-1 is a Wnt-1 and beta-catenin-responsive oncogene. Genes Dev 14(5):585-595, 3/2000. PMCID: PMC316421.
42. Pennica D, Swanson T, Welsh J, Roy M, Lawrence D, Lee J, Brush J, Taneyhill LA, Deuel B, Lew M, Watanabe C, Cohen RL, Melhem M, Finley G, Quirke P, Goddard AD, Hillan KJ, Gurney AL, Botstein D, Levine AJ. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A 95(25):14717-14722, 12/1998. PMCID: PMC24515.
Other Articles
1. Welsh J. Book review: Textbook of lung cancer, 2nd edition. Int J Radiat Oncol Biol Phys 73(4):1283, 3/2009.

Abstracts

1. Welsh J, Likacheva A, Byers LA, Bhardwaj V, Diao L, Wang J, Ang KK, Romaki R, Kim E, Heymach JV. Implications of KRAS mutations on outcomes in non-small cell lung cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 84(35):S70 (#172), 10/2012.
2. Wang H, Gomez DR, Komaki R, Welsh J, O’Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Liao Z. Improved survival outcomes in non-small cell lung cancer patients with incidental concurrent use of beta-blockers and definitive radiation therapy. Int J Radiat Oncol Biol Phys 84(35):S587 (#2901), 10/2012.
3. Juloori A, Shirvani SM, Allen PK, Komaki R, Liao Z, Welsh J, Gomez DR, Heymach JV, Chang JY. Limited-stage small cell lung cancer in the contemporary period: impact of new technologies on outcomes. Int J Radiat Oncol Biol Phys 84(35):S592 (#2994), 10/2012.
4. Gomez DR, Liao K, Chang JY, Liao Z, Shirvani SM, Komaki R, Welsh J, Swisher SG, Heymach JV, Smith BD. Patient selection for treatment modality in stage III non-small cell lung cancer: a population-based analysis. Int J Radiat Oncol Biol Phys 84(35):S540 (#2859), 10/2012.
5. Shirvani SM, Juloori A, Gomez DR, Allen PK, Komaki R, O’Reilly MS, Liao Z, Welsh J, Papdimitrakopoulou V, Chang JY. Patterns of failure for limited-stage small cell lung cancer following definitive radiation in the modern era. Int J Radiat Oncol Biol Phys 84(35):S595 (#3004), 10/2012.
6. Komaki R, Allen P, We Xi, Blumenschein G, Wistuba I, Lee J, Welsh J, O’Reilly M, Tang X, Hong W. Phase II trial of erotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer has shown a favorable response profile. Int J Radiat Oncol Biol Phys 84(35):S68 (#169), 10/2012.
7. Fakhreddine M, Liao Z, Zhuang Y, Bhardwaj V, Tucker S, Skinner H, Heymach J, Gomez D, Komaki R, Welsh J. Poor glycemic control during radiochemotherapy contributes to reduced local control and overall survival in patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84(35):S69 (#171), 10/2012.
8. Zhuang Y, Gomez DR, Komaki R, O’Reilly MS, Welsh J, Lin SH, Chang JY, Jeter M, Liao Z. Prognostic factors for overall survival in stage IIIA/IIIB non-small cell lung cancer after definitive (chemo)radiation therapy. Int J Radiat Oncol Biol Phys 84(35):S591 (#2993), 10/2012.
9. McAvoy S, Komaki R, Allen P, Rineer J, Liao Z, Chang J, Welsh J, Palmer M, Cox J, Gomez D. Reirradiation with proton beam therapy or intensity modulated radiation therapy for non-small cell lung cancer: an institutional experience. Int J Radiat Oncol Biol Phys 84(35):S608 (#3037), 10/2012.
10. Gomez DR, Liao K, CHang JY, Liao Z, Shirvani SM, Komaki R, Welsh J, Heymach JV, Swisher SG, Smith BD. Treatment modality and other prognostic factors for overall survival in stage III non-small cell lung cancer: a population-based analysis. Int J Radiat Oncol Biol Phys 84(35):S540 (#2858), 10/2012.
11. Komaki R, Allen P, Wei X, Blumenschein G, Wistuba I, Lee J, Welsh J, O'Reilly M, Tang X, Hong W. Phase II trial of erotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer has shown a favorable response profile. J Thorac Oncol 7(15):S279 (#281), 9/2012.
12. Blum M, Hayashi Y, Xiao L, Suzuki A, Sabloff B, Maru D, Taketa T, Welsh J, Lin S, Lee J, Bhutani M, Weston B, Hofstetter W, Swisher S, Ajani J. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with esophageal cancer (EC). J Clin Oncol 30(suppl):abstr e14547, 6/2012.
13. Cheedella S, Suzuki A, Correa A, Hofstetter W, Mehran R, Rice D, Maru D, Vaporciyan A, Taketa T, Blum M, Welsh J, Lin S, Lee J, Bhutani M, Weston B, Walsh G, Swisher S, Ajani J. Association of clinical complete response (cCR) after preoperative chemoradiation and pathological complete response (pathCR) in patients with gastroesophageal cancer (GEC) and indispensability of trimodality therapy (TMT). J Clin Oncol 30(suppl):abstr 4086, 6/2012.
14. Shirvani S, Jiang J, Chang J, Gomez D, Welsh J, Swisher S, Buchholz T, Smith B. Comparative effectiveness of five treatment strategies for early-stage non-small cell lung cancer in the elderly. J Clin Oncol 30(suppl):abstr 7062, 6/2012.
15. Suzuki A, Xiao L, Taketa T, Blum M, Welsh J, Lin S, Weston B, Lee J, Bhutani M, Rice D, Mehran R, Maru, Erasmus J, Hofstetter W, Swisher S, Ajani J. Customization of treatment for patients with esophageal adenocarcinoma (EAC) who achieve clinical complete response (cCR) after chemoradiation using initial standardized uptake value (iSUV) of 18f-fluorodeoxyglucose PET. J Clin Oncol 30(suppl):abstr 4069, 6/2012.
16. Amini A, Welsh J, Allen P, Xiao L, Suzuki A, Hayashi Y, Blum M, Hofstetter W, Liao Z, Lee J, Bhutani M, Komaki R. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. J Clin Oncol 30(suppl):abstr e14669, 6/2012.
17. Byers L, Nilsson M, Masrorpour F, Wang J, Diao L, Bhardwaj V, Welsh J, Girard L, Coombes K, Weinstein J, Lippman L, Glisson B, Minna J, Heymach J. Investigation of PARP1 as a therapeutic target in small cell lung cancer. J Clin Oncol 30(suppl):abstr 7096, 6/2012.
18. Taketa T, Correa A, Suzuki A, Blum M, Lee J, Welsh J, Lin S, Maru D, Erasmus J, Bhutani M, Weston B, Rice D, Swisher S, Hofstetter W, Ajani J. Outcome of 58 trimodality-eligible esophagogastric cancer (EC) patients who achieved clinical complete response (cCR) after preoperative chemoradiation but then declined surgery. J Clin Oncol 30(suppl):abstr 4078, 6/2012.
19. Bhardwaj V, Likhacheva A, Byers L, Komaki R, Kim E, Heymach J, Welsh J. Establishing role of KRAS mutation on NSCLC radio-sensitivity. Proceedings of the American Association for Cancer Research Annual Meeting (#3454), 4/2012.
20. Cortez M, Bhardwaj V, Zhan Y, Byers L, Calin G, Heymach J, Welsh J. Mir-200c overexpression radiosensitizes lung cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting (#1099), 4/2012.
21. Benveniste M, Betancourt S, Godoy M, Mawlawi O, Welsh J, Munden R. New era of radiotherapy: an update in radiation-induced lung disease. Proceedings of the Scientific Assembly and Annual Meeting of the Radiological Society of North America, 11/2011.
22. Amini A, Welsh J, Yang J, McBurney ML, Williamson MT, Karhade M, Allen P, Erasmus J, Dong L, Liao Z. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int J Radiat Oncol Biol Phys 81(2s):S110-S111, 10/2011.
23. Ciura KT, Welsh J, Nguyen N, Palmer M, Paolini M, Bluett J, Mohan R, Gomex D, Cox JD, Chang J. Evaluating stereotactic body radiotherapy with protons to reduce chect wall dose in the treatment of lung cancer. Int J Radiat Oncol Biol Phys 81(2s):S87, 10/2011.
24. Welsh J, Kim E, Amin A, Allen P, Chang J, Komaki R, Nguyen N, Holt J, Erdman D, Stea B. Phase II safety data of erlotinib with concurrent whole-brain radiation therapy for patients with brain metastasis from non-small cell lung cancer. Int J Radiat Oncol Biol Phys 81(2s):S136, 10/2011.
25. Komaki R, Blumenschein GR, Wistuba II, Lee J, Allen PK, Wei X, Welsh J, O'Reilly MS, X Tang, Hong W. The phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer has shown a favorable response profile. Int J Radiat Oncol Biol Phys 81(2s):S591-S592, 10/2011.
26. Welsh J, Riley B, Palmer MB, Amin MV, Komaki R, Gomez D, Liao Z, Hofstetter WL, Ajani A, Cox JD. Intensity-modulated proton therapy allows dose escalation and normal-tissue sparing in locally advanced distal esophageal tumors. Int J Radiat Oncol Biol Phys 78(3s):S808, 11/2010.
27. Likhacheva A, Thomas J, Kim E, Allen P, Komaki R, Cox J, Herbst R, Welsh J. Predictive implications of KRAS and EGFR gene mutation in non-small cell lung cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 78(3s):S128-129, 11/2010.
28. Welsh J, Zhan Y, Likhacheva A, Komaki R. Radiation-induced c-MET expression sensitizes lung cancer cells to c-MET antagonists. Eur J Cancer 8(7):162 (#508), 11/2010.
29. Gao S, Chang JY, Welsh J, Komaki R, Balter P. Influence of the couch and immobilization device used during stereotactic body radiotherapy on skin dose. Int J Radiat Oncol Biol Phys 75(3s):S682, 11/2009.
30. Palmer MB, Vedam S, Komaki R, Welsh J. Intensity modulated radiation therapy (IMRT) benchmarks for thoracic malignancies. Int J Radiat Oncol Biol Phys 75(3s):S476, 11/2009.
31. Welsh J, Thomas J, Wei X, Allen P, Mitchell K, Gao S, Komaki R, Chang J. Skin toxicity and pain in patients treated with stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 75(3s):S61, 11/2009.
32. Welsh J, Ellsworth R, Mahadevan D, Bearss D, Komaki R, Stea B. A c-MET receptor tyrosine kinase inhibitor offers increased radiosensitization in NSCLC after pretreatment with erlotinib. J Thorac Oncol 4(9, s1):S957 (#P3.241), 9/2009.
33. Ellsworth R, Welsh J, Mahadevan D, Bearrs D, Hsieh D, Fjerstad K, Marsella M, Sanan A, Badrudojja M, Stea B. The radiosensitizing effects of a novel tyrosine kinase inhibitor, MP470 in glioblastoma multiforme stem cells. Int J Radiat Oncol Biol Phys 72(1s):S714-S715, 9/2008.
34. Ellsworth R, Welsh J, Kumar R, Fjerstad K, Green S, Nagle R, Stea B. CD133 expression before and after radiation in glioblastoma multiforme. Proceedings of the American Association for Cancer Research Annual Meeting (#1010), 4/2008.
35. Kumar R, Welsh J, Nagle RB, Green S, Stea BD. Association between Rad-51 levels and survival in patients with glioblastoma multiforme treated with radiation therapy. Int J Radiat Oncol Biol Phys 69(3s):S63-S64, 11/2007.
36. Schefter TE, Welsh J, Gaspar L, Kavanagh B. Normal liver V30% and mean liver dose predicts the maximum normal liver volume reduction after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys 69(3s):S596, 11/2007.
37. Welsh J, Mahadevan D, Bearss D, Stea B. Sensitization of a glioblastoma multiform (GBM) cell line by MP470: a novel c-MET antagonist. Int J Radiat Oncol Biol Phys 69(3s):S100, 11/2007.
38. Welsh J, Mahadevan D, Dougherty G, Stea B. A c-MET receptor tyrosine kinase inhibitor radiosensitizes glioblastoma cells by reducing dsDNA repair, mediated through decreased Rad-51. Proceedings of the Annual Meeting of the American Radium Society, 5/2007.
39. Welsh J, Garland L, Stea BD, Philip-Norton R. A phase II study to determine the efficacy of tarceva (erlotinib hydrochloride) with concurrent whole brain radiation therapy (WBRT) in patients with brain metastases from non-small cell lung cancer. J Thorac Oncol 2(8):S763, 2007.
40. Welsh J, Mahadevan D, Dougherty G, Stea B. c-MET inhibition radiosensitizes melanoma by inhibiting double strand DNA repair. Int J Radiat Oncol Biol Phys 66(3s):S557-S558, 11/2006.
41. Watchman C, Hamilton R, Welsh J. Implanted marker movements during prostate IMRT. Proceedings of the American Association of Physicists in Medicine Annual Meeting (#5897), 7/2006.
42. Welsh J, Gabayan A, Sanan A, Stea B. GliaSite radiotherapy boost as part of initial treatment of malignant gliomas: A multi-institutional analysis. Brachytherapy 5(2):78-79, 4/2006.

Book Chapters

1. Bhardwaj V, Cortez A, Fakhreddine M, Welsh J. Biologic principles of radiosensitization. In: Cancer Nanotechnology: Principles and Applications in Radiation Oncology. Ed(s) SH Cho, S Krishnan. Taylor and Francis Books, Inc: Boca Raton, FL, 15-24, 2013. ISBN: 9781439878750.
2. Lin S, Welsh J. Advanced-stage (III-IV) non-small cell lung cancer. In: Radiation Oncology: A Question-Based Review. Ed(s) Hristov B, Christodouleas J, Lin S. Lippincott Williams & Wilkins, 209-221, 2010.

Manuals, Teaching Aids, Other Teaching Publications

1. Laino C, Welsh J. Stereotactic body radiation therapy called new standard of care for inoperable early lung cancer. 31, 24. Oncology Times, 51-52, 12/2009.

Grant & Contract Support

Title: Evaluating miR34a as a radiation sensitizer for the treatment of lung cancer
Funding Source: Family of Mr. M. Adnan Hamed
Role: Principal Investigator
Duration: 5/1/2012 - present
 
Title: Circulating miR-200 family as biomarker of resistance to radiation and erlotinib in lung cancer
Funding Source: Lung Cancer Research Foundation
Role: Principal Investigator
Duration: 11/1/2011 - 10/31/2012
 
Title: Evaluating BCL-2 expression as a biomarker for esophageal cancer
Funding Source: The University of Texas MD Anderson Cancer Center
Role: Collaborator
Duration: 8/1/2011 - 7/31/2013
 
Title: Modulating microRNA to radiosensitize non-small cell lung cancer through reversing the epithelial-mesenchymal transition
Funding Source: Lung Cancer Research Foundation
Role: Principal Investigator
Duration: 11/1/2010 - 10/31/2012
 
Title: Evaluating modulation of serum c-Met in response to EGFR antagonists and radiation for the treatment of lung cancer
Funding Source: Paul Calabresi K-12 Grant, NIH
Role: Principal Investigator
Duration: 10/1/2010 - 8/1/2013
 
Title: c-Met Antagonist (MK-2461/8033) as a Potential Radiosensitizer in Non-Small Cell Lung Cancer
Funding Source: Merck and Co.
Role: Principal Investigator
Duration: 5/22/2009 - 12/30/2010
 
Title: Looking at EGFR mutation status from phase II investigator initiated trials of erlotinib plus radiation in patients with brain metastasis from non-small cell lung cancer
Funding Source: OSI Pharmaceuticals, Inc.
Role: Principal Investigator
Duration: 2/26/2009 - 2/26/2012

Last updated: 6/30/2014